HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.
Hologic (HOLX) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.01 per share a year ago.
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
HOLX's fiscal Q4 2025 earnings may face limits as macro pressures and slow Diagnostics curb momentum.
The maker of women's health products rejected a $16 billion offer from the parties in May.